Results 201 to 210 of about 354,339 (315)

Methylphenidate Treatment and Risk of Psychotic Disorder.

JAMA Psychiatry
Healy C, O'Hare K, Lång U, Metsälä J, Pulakka A, McGrath J, Migone M, Keating D, Romaniuk L, Gyllenberg D, Kajantie E, Perrett G, Hill J, Elwert F, Kelleher I.   +14 more
europepmc   +1 more source

Exploring the preferences of multiple stakeholder groups for family involvement in early intervention services for psychosis: A cross-sectional mixed-methods study. [PDF]

PLOS Ment Health
Martin H, Xavier S, Taksal A, Levasseur MA, Iyer SN.   +4 more
europepmc   +1 more source

Correction: Reasons for disengagement in first-episode psychosis– perspectives from service users and their caregivers

BMC Psychiatry
Yi Chian Chua, Kumarasan Roystonn, K. Pushpa, Swapna Verma, Charmaine Tang   +4 more
doaj   +1 more source

Calcified frontal neurocysticercosis presenting with acute psychosis in a non-endemic context: a case report. [PDF]

Front Psychiatry
Alfahal MS, Jalkhi T.
europepmc   +1 more source

Demographic, physical and mental health assessments in the adolescent brain and cognitive development study: Rationale and description [PDF]

, 2018
Barch, Deanna M, et al,
core   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Measuring feelings of dehumanization in people who experience psychosis: development and validation of the self-Dehumanization in Psychosis Scale (DiPS). [PDF]

Schizophr Bull
Jenkins TA, Jacobsen P, Chadwick P.
europepmc   +1 more source

An Exploration of Emotion Regulation in Psychosis [PDF]

, 2009
Gillanders, David, Harper, Sean, Livingstone, Karen   +2 more
core   +1 more source

Dose reduction and discontinuation of antipsychotics in psychotic disorders: a systematic review of qualitative studies and meta-synthesis. [PDF]

Schizophrenia (Heidelb)
Aprile SF, Rodolico A, Munafò A, Bighelli I, Caraci F, Leucht S.   +5 more
europepmc   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source